|
Prostate carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
We correlated LSD1 and JMJD2A expression with known mediators of prostate cancer progression: VEGF-A and cyclin A1.
|
23384557 |
2013 |
|
Tumor Cell Invasion
|
0.090 |
PosttranslationalModification
|
phenotype |
BEFREE |
Our studies provide insights into the epigenetic control of AP1 and tumor invasion and suggest that KDM4A could be an important therapeutic target for inhibiting invasive SCC growth and metastasis.
|
23633675 |
2013 |
|
Malignant neoplasm of prostate
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Our results show that the KDMs JARID1B, PHF8, KDM3A, KDM3B and KDM4A were highly expressed in clinical PrCa samples.
|
22120715 |
2012 |
|
Carcinogenesis
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
JMJD2A is a transcriptional cofactor and enzyme that catalyzes demethylation of histone H3 lysines 9 and 36 and is overexpressed in human tumors, but its role in oncogenesis remains unclear.
|
22134899 |
2012 |
|
Prostate carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Our results show that the KDMs JARID1B, PHF8, KDM3A, KDM3B and KDM4A were highly expressed in clinical PrCa samples.
|
22120715 |
2012 |
|
Tumor Cell Invasion
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
These data imply that silencing JMJD2A gene could result in cell cycle change and proliferation inhibition, and lead to suppress tumor cell invasion and migration.
|
21962223 |
2011 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Jumonji domain containing 2A (JMJD2A), a member of the JmjC domain‑containing family of JMJD2 proteins, is capable of regulating cancer‑associated genes, including genes involved in the cell cycle, proliferation, apoptosis, invasion and metastasis.
|
30720092 |
2019 |
|
Neoplasm Metastasis
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
Both JMJD2A and LDHA expression were positively correlated with the tumor stage, metastasis and clinical stage.
|
28693517 |
2017 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Previous studies have identified histone demethylase KDM4A to be a key epigenetic priming factor for the invasive squamous cell carcinoma growth and metastasis.
|
29113308 |
2017 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
We found that overexpression of lysine-specific demethylase 4A (KDM4A, also known as JMJD2A) was positively correlated with Gleason score and metastasis in human prostate tumors.
|
26731476 |
2016 |
|
Neoplasm Metastasis
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
Downregulation of JMJD2A led to reduced endometrial carcinoma RL95-2 and ISK cell proliferation, invasion and metastasis as asessed with cell counting kit-8, cell migration and invasive assays.
|
24815446 |
2014 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3.
|
25193278 |
2014 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Our studies provide insights into the epigenetic control of AP1 and tumor invasion and suggest that KDM4A could be an important therapeutic target for inhibiting invasive SCC growth and metastasis.
|
23633675 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We found expression of several JMJD2 family genes upregulated in CP-resistant cells, with JMJD2B expression being upregulated in all three CP-resistant NSCLC cell lines.
|
30967636 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
In addition, the interaction with the JMJD2A and JMJD2D epigenetic regulators may be important in the ability of ETV2 to reprogram cells, modulate normal and cancer stem cells, and affect spermatogenesis.
|
29393482 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Importantly, JMJD2A has been implicated as an oncogene in various cancers by regulating proliferation.
|
28212444 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
KDM4A SNP-A482 had a minor allele (C) frequency of 18.8% and a major allele (A) frequency of 81.2% in our Asian NSCLC (adenocarcinoma) patients.
|
28059867 |
2017 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Restoring the KDM4A expression contributed to bypass of miR-137-induced senescence and inhibition of endogenous miR-137 with an miRNA sponge-compromised Ras-induced senescence. miR-137 levels are significantly reduced in human pancreatic tumors, consistent with previous studies revealing a defective senescence response in this cancer type.
|
26904954 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Our results suggested that JMJD2A was significantly overexpressed in NSCLC samples and cell lines.
|
26498874 |
2016 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
We primarily discuss the role of KDM4A in cancer development and the importance of KDM4A as a potential therapeutic target.
|
25633974 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In this report, we demonstrate that coding SNP-A482 within the lysine tridemethylase gene KDM4A/JMJD2A has different allelic frequencies across ethnic populations, associates with differential outcome in patients with non-small cell lung cancer (NSCLC), and promotes KDM4A protein turnover.
|
25564517 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In summary, our findings implicate that SIRT2 suppresses non-small cell lung cancer growth through targeting JMJD2A and SIRT2 activator may serve as candidate drug for NSCLC therapy.
|
25719312 |
2015 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Previous data demonstrate that JMJD2A is a cancer-associated gene and may be involved in human breast cancer by demethylation of H3K9me3.
|
21962223 |
2011 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Results from knockdown of JMJD2A, overexpression of JMJD2A, Co-immunoprecipitation (Co-IP) assay, dual luciferase reporter gene assay and chromatin immunoprecipitation (ChIP) elucidated molecular mechanisms of JMJD2A action in breast cancer progression.
|
24886710 |
2014 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of Sp1 autoregulation by JMJD2A contributed to Sp1 expression pattern in breast cancer.
|
25193278 |
2014 |